Home Healthcare Global Bipolar Disorder Treatment Market
global bipolar disorder treatment market

Bipolar Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Mood Stabilizer, Anti-Convulsant, Anti-Psychotic Drug, Anti-Depressant, Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

  • Published Date: Jul 2022
  • Pages: 113
  • Format: PDF
  • Report ID: PM1306
  • Base Year: 2021
  • Historical Data: 2018-2020

Report Summary

The global bipolar disorder treatment market was valued at USD 4.28 billion in 2021 and is expected to grow at a CAGR of 3.1% during the forecast period. The growth of the bipolar disorder treatment market is attributed to the advancements in innovation supporting the market development, as the utilization of cell phones, smartwatches, and wearable gadgets works with exact recognition of a patient's state of mind and mental state and catches physiological, conduct, and natural information. Other than the appearance of online self-administration apparatuses for mental issues empowers ideal intercession and better adherence to recommended cures.

Bipolar Disorder Treatment Market Size
Know more about this report: Request for sample pages

Expanding predominance of bipolar disorder and innovative headways that work with exact recognition of a patient's state of mind and mental state are a couple of the elements driving the treatment market. For example, the use of tricyclic anti-depressants has declined over the years attributable to the higher occurrence of secondary effects in contrast with different medications utilized for the disorder treatment.

Bipolar Disorder Treatment MarketKnow more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
In addition, states of a few countries are designating assets for research in the field of bipolar disorder and starting mindfulness missions to kill the disgrace related to bipolar disorder and further develop treatment and adherence rates among everybody. Likewise, logical bodies and clinical establishments assume a functioning part by leading exploration studies and creating novel medications and medicines.

For example, the Salk Institute for Biological Studies and the Johns Hopkins University of Medicine sent off a drive in 2016 worth USD 15.4 million to foster new examinations and medication evaluating strategies for bipolar disorder and schizophrenia.

However, large numbers of medications utilized in treating bipolar problems have related secondary effects, including dependence of the body on the medication, diabetes and cholesterol issues, obscured vision, harm to the liver, and thyroid, among others. Studies have likewise connected some medications to serious secondary effects like causing renal disappointment and teratogenic changes in the hatchling whenever utilized by pregnant ladies. Further, an enormous number of times, bipolar turmoil might be misdiagnosed as gloom or a behavioral condition which may likewise bring down the finding and treatment paces of this psychological problem.

The patent expiry of blockbuster medicines in treatment market may affect the market elements. The medications in the market face serious contests because of the raid of conventional medications as treatment choices for bipolar disorder. For example, patent termination of blockbuster medications like Seroquel, Zyprexa, Risperdal, and Invega will probably limit market development attributable to the rising nonexclusive substitutes on the lookout.

Report Segmentation

The market is primarily segmented based on drug class, mechanism of action, distribution channel, and region.

By Drug Class

By Mechanism Of Action

By Distribution Channel

By Region

  • Mood stabilizer
  • ¬†Anticonvulsant
  • Antipsychotic Drug
  • Antidepressant Drug
  • Other Classes of Drug
  • Selective Serotonin Reuptake Inhibitor (SSR)
  • Serotonin Norepinephrine Reuptake Inhibitor
  • Tricyclic Antidepressant Drug
  • Beta-Blockers
  • Others
  • Hospitals & Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Russia, Spain)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Anti-psychotic drugs to hold major market share

Based on drug class, the antipsychotic drug accounted for the largest revenue share in the bipolar disorder treatment market. It is utilized with the selective serotonin reuptake inhibitor (SSRI) as a feature of a blend treatment and has exhibited excellent outcomes, subsequently making more doctors decide on these prescriptions. Antipsychotic drugs are utilized as a momentary treatment for bipolar disorder to control insane side effects, like hallucinations, delusions, or mania symptoms. These side effects might happen during intense craziness or severe sorrow. Some additionally treat bipolar disorder, and a few have exhibited long-held esteem in forestalling future episodes of delusions or mania symptoms. In individuals with bipolar disorder, antipsychotics are likewise utilized "off labels" as narcotics for a sleeping disorder, tension, or potential disturbance.

Frequently, they are taken with a temperament balancing out drug and can diminish the side effects of mania until mood stabilizers produce complete results. A few antipsychotics appear to assist with settling states of mind all along. Thus, they might be utilized alone as a drawn-out treatment for individuals who don't endure or answer lithium and anticonvulsants. A couple of antipsychotic drugs incorporate Abilify), Saphris, Vraylar, Clozaril, Latuda, Zyprexa, Seroquel, Risperdal, and Geodon.

Anticonvulsants act as viable misery temperament stabilizers by lightening the burdensome side effects of bipolar disorder without hastening madness. These medications beat the restrictions looked by conventional antidepressants as they settle the state of mind without setting off craziness or causing episode speed increase. The broad utilization of anticonvulsants, as a solitary medication or as a piece of mixed treatments, will rapidly drive the development of the bipolar disorder treatment market portion over the estimated period.

Selective serotonin reuptake inhibitor mechanism of action to witness high growth

Based on the mechanism of action, the helpful activities of SSRIs have their basis in expanding insufficient serotonin, one of the significant reasons for depression. SSRIs apply movement by hindering serotonin reuptake, subsequently developing serotonin action. SSRIs significantly affect different synapses, like dopamine or norepinephrine. SSRIs additionally have moderately fewer aftereffects because of fewer impacts on adrenergic, cholinergic, and histaminergic receptors. SSRIs restrain the serotonin carrier (SERT) at the presynaptic axon terminal. By restraining SERT, an expanded measure of serotonin (5-hydroxytryptamine or 5HT) stays in the synaptic parted and can invigorate postsynaptic receptors for a more broadened period.

The market demand in North America is expected to witness significant growth

North America is estimated to showcase the most considerable bipolar disorder treatment market growth during the forecast period. This can be credited to the high feelings of anxiety, short rest, and pattern of substance maltreatment among the populace. What's more, government drives for making mindfulness and supporting patients with bipolar disorder are likewise expected to fuel market development around here. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA) extended its help for emotional well-being treatment and recovery; in 2016. Such drives will probably support the development of this local portion in the figure period.

Asia Pacific is supposed to enroll higher CAGR over the projected period when contrasted with different districts, which can be credited to the high predominance of mental problems around here. As indicated by information distributed by WHO, India and China rank among the nations most impacted by mental problems like tensions, schizophrenia, and bipolar disorder. Other than government drives, for example, the Healthy Asia Pacific 2020 drive, sent off in 2014 by Asia Pacific Economic Cooperation (APEC) body, will probably move the market around here.

Competitive Insight

Some of the major market players operating the bipolar disorder treatment market include AbbVie Inc., Allergan plc, AstraZeneca, Eli Lilly, Gedeon Richter Plc., GlaxoSmithKline plc, H. Lundbeck A/S, Indivior PLC., Intra-Cellular Therapies Inc., Janssen Pharmaceuticals, Johnson & Johnson, Minerva Neurosciences, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., and Takeda Pharmaceutical Company Limited.

Recent developments

  • In February 2022, Neurocentria Inc. got the Food and Drug Administration endorsement to direct an acute stage IIb/III human clinical preliminary to test the viability and well-being of its driving medication up-and-comer NRCT-101SR contrasted with fake idle treatment in grown-ups with ADHD.
  • In January 2022, Green Valley got the endorsement letter from the FDA on the IND application for the worldwide multi-focus stage II clinical preliminary of Oligomannate, the organization's creative medication.

Bipolar Disorder Treatment Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 4.28 billion

Revenue forecast in 2030

USD 5.56 billion

CAGR

3.1% from 2022 - 2030

Base year

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Segments covered

By Drug Class, By Mechanism of Action, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

AbbVie Inc., Allergan plc, AstraZeneca, Eli Lilly, Gedeon Richter Plc., GlaxoSmithKline plc, H. Lundbeck A/S, Indivior PLC., Intra-Cellular Therapies Inc., Janssen Pharmaceuticals, Johnson & Johnson, Minerva Neurosciences, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., and Takeda Pharmaceutical Company Limited.

Key Take-Away
Polaris Market Research
Global Bipolar Disorder Treatment Market Size Report, 2022 - 2030